OncoSec Medical Inc (ONCSQ)

[hschlauch]

Yeah, I'm also in agreement with Chickpea. A response rate of 64%-75% in the retrospective study is unheard of in metastatic melanoma. Even the toxic yervoy and opdivo combination couldn't reach that level in a SUB-POPULATION of metastatic melanoma patients.

I think it would be hard to get to that level-equivalent (approximately 50% like you mentioned) in the current combination trial, but if it does approach that level of response, then we may be setting a VERY HIGH BAR. The epacadostat and pembrolizumab ECHO 202 phase 1 trial demonstrates the clinical significance and market excitement for successful small trials with widely-applicable treatment platforms. A 50% response rate (in non-responders) is completely unheard of for metastatic melanoma, and on top of that the EP IL-12 platform may work in other indications (e.g. merkel cell, head and neck).